Skip to main content
High Exposure of Intravenous Alemtuzumab Is Associated with Increased Risk of Double-Stranded DNA Viral Infections in Patients with Non-Malignant Disease Undergoing Allogeneic HCT.
Fludarabine Pharmacokinetic-Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Mismatched Allogeneic Hematopoietic Cell Transplantation.
Epidemiology of Diffuse Alveolar Hemorrhage in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients.
Impact of Race and Ethnicity on Outcomes after Umbilical Cord Blood Transplantation.
Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia.
A Cure for Sickle Cell Disease.
Cyclophosphamide and thiotepa increases risk of transplant-associated thrombotic microangiopathy.
Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols.
The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities.
Development of a Safety Surveillance Plan for The Academic Medicine Sponsor Performing First in Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy.